New Study Shows Promise for Cancer Patients Avoiding Surgery
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources.
Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content.
A promising new study presented at the American Association for Cancer Research's annual meeting shows that immunotherapy could help many cancer patients avoid surgery. Researchers found that 92 percent of patients who received only an immune-based treatment remained cancer-free two years later.
Why It Matters
The findings suggest that for some cancers, surgery and its difficult recovery may not always be necessary. This could dramatically change standard treatment approaches, offering a less invasive option with fewer long-term side effects for patients.
Accuray Radixact machine with patient being positioned and accompanied by therapist on August 26-27 in Geneva, Swiss Confederation.
Accuray Radixact machine with patient being positioned and accompanied by therapist on August 26-27 in Geneva, Swiss Confederation.What to Know
The study, published in the New England Journal of Medicine, explored whether immune checkpoint inhibitors could help shrink tumors without the need for surgery. These drugs work by boosting the body's natural ability to detect and destroy cancer cells.
Among patients with rectal cancer, a previous study found that all 42 participants who received the therapy remained cancer-free after four years. In this new study, which included patients with other types of cancers, such as colon, esophageal, stomach, and gastroesophageal junction cancers, 92 percent had no signs of disease after two years.
Maureen Sideris, 71, was one of the patients who benefited from the new approach, Time reported. Diagnosed with gastroesophageal junction cancer, she initially faced the prospect of major surgery, chemotherapy, and radiation. Instead, she opted into the experimental immune-based treatment, receiving monthly infusions for nine months. Two years later, her cancer remains undetectable.
Dr. Andrea Cercek of Memorial Sloan Kettering Cancer Center, who led the study, noted that even patients with more advanced Stage III cancers responded well. The treatment was effective even when cancer had spread to nearby lymph nodes, offering hope for a broader group of patients.
Researchers plan to follow patients for a longer period to determine if the benefits translate into higher survival rates. They are also investigating why some patients did not respond in hopes of refining the treatment even further. The checkpoint inhibitor used, dostarlimab, has already been fast-tracked by the FDA for certain cancers with specific genetic mutations.
What People Are Saying
Dr. Andrea Cercek, Memorial Sloan Kettering Cancer Center to TIME: "Therapy like this can lead to significant tumor downstaging and improve patients' quality of life."
Maureen Sideris, study participant to TIME: "The infusions were the easiest part. I'm so grateful I could avoid surgery."
What Happens Next
Researchers are continuing trials to determine the long-term effectiveness of this treatment across different cancer types and stages. If results remain strong, immunotherapy could become a standard first-line option for many patients, reshaping cancer care for years to come.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Newsweek
14 hours ago
- Newsweek
Mom Captures Moment With Toddler, Just Days Later She'll Be Gone
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. A mom from Ontario, Canada, captured a moment with her toddler, not knowing it would be one of the last memories together. Tamara Spearing, 31, posted a reel on Instagram holding and kissing her daughter. Days later, Gwendolyn was gone. Spearing told Newsweek that she was pregnant with Gwendolyn at 26. She had just bought her first home and was working two jobs. From left: Tamara Spearing holds her toddler daughter in her arms and kisses her head in dark lighting. From left: Tamara Spearing holds her toddler daughter in her arms and kisses her head in dark lighting. @tamaraspearing_ Spearing's days were full—friends, family, healthy living and big dreams. "I had full trust in the universe and what life was going to look like for me," she said. "That was until my life drastically changed within a matter of days." Gwendolyn was what Spearing called her "pleasant surprise." While her pregnancy was unplanned, she said she quickly embraced it. "I remember daydreaming what my child would look like; who they would grow up to be," Spearing said. "For me, my pregnancy was just the beginning of something amazing, and I was so, so excited to be a mama." At 28 weeks and five days, Spearing went into premature labor—a terrifying experience that unfolded while she was visiting Gwendolyn's father, who had recently been admitted to the ICU after a serious accident. "I didn't want to believe it as I was hardly into my third trimester," she added. Spearing walked herself to the labor and delivery floor, where she was met by a team of specialists. "I faintly remember looking over to the bedside nurse, asking her what I should expect and begging and pleading for a safe arrival of my baby," Spearing said. "I told the nurse, 'That wasn't my birth plan. I don't even have a nursery at home.' "She looked at me and said, 'Hunny, there is no such thing as a birth plan'," Spearing said. Within two hours and just three pushes, Gwendolyn was born at 2 pounds, 10 ounces. What followed were months of medical hurdles. Gwendolyn was diagnosed with Esophageal Atresia with Tracheoesophageal Fistula (EA/TEF)—a rare congenital condition where the esophagus doesn't connect to the stomach. Gwendolyn's prematurity brought additional complications: brain bleeds, underdeveloped lungs, multiple surgeries, code blues (where a patient requires resuscitation or is in need of immediate medical attention) and long hospital stays. Overall, Gwendolyn spent 170 days in hospital before being cleared to go home. Against the odds, she was thriving and hitting every milestone, according to her mom. "Appointments were further and farther between; she was attending playgroups and making friends; she was learning and discovering as a child should be at her age," Spearing said. "For the first time in her life, she was able to be just a kid." Then, on April 5, their world came crashing down. "For us, it was a normal day," Spearing added. "Little did I know this day would change my life forever." That evening, Gwendolyn's heart stopped. The autopsy provided no definitive cause. Some specialists suspect a catastrophic seizure or undetected heart failure. Spearing explored genetic counseling in the aftermath but was overwhelmed by the lack of answers. "I may never know why my daughter passed, and although I know now sometimes things just aren't meant to have an explanation, I still lay awake at nights contemplating the days leading up to her death and wondering if there was something I missed and if there was something apparent; maybe I could have saved her," Spearing said. Now, three years later, grief remains a constant companion. Spearing said that she barely remembers anything after Gwendolyn passed. "I was very angry. I lost trust in the universe and I questioned my beliefs," she added. "I wanted nothing more than to wake up from this nightmare that I was living in. I couldn't understand why a beautiful, innocent soul, who fought so hard to be here, only to be taken so abruptly." Out of her grief, Spearing created The Gwen Effect, a foundation honoring her daughter's legacy. It supports premature infants and children with complex medical conditions, funds research, and offers community support for grieving families. "I found a way of turning my pain into a purpose," Spearing said. "I continue to speak on grief and life after loss as I truly believe it is something that needs to be talked about more." The foundation's mission is clear: raise awareness, provide resources and create spaces where both grief and hope can coexist. Through it, Gwendolyn continues to touch lives. "Gwen was a ray of sunshine," Spearing said. "She was born tiny but mighty. Her passion for life while in and out of hospital showed us and many others how precious our time is. She was strong and brave."
Newsweek
19 hours ago
- Newsweek
Can Tackling Addictions Reduce Medicaid Costs?
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Discussions around Medicaid costs have become more heated than ever in recent months as President Donald Trump's administration tries to push its budget bill through the legislative ranks. House Republicans have instructed the House Committee on Energy and Commerce to slash $880 billion in spending over the next decade, with Medicaid making up 93 percent of the committee's budget. As a result, the amount of money the federal Medicaid program needs to provide health care services for more than 70 million Americans has been under dispute, with some arguing there is significant waste and misuse of money in the system, while others have warned cuts would leave millions of vulnerable people without access to health care. While lawmakers continue debating the divisive legislation, experts have discussed with Newsweek whether there could be another way of reducing Medicaid costs—tackling substance use disorders. Medicaid enrollees with substance use disorders require significantly higher health costs than those without—around $1,200 per month on average compared to $550, according to KFF. Around 7.2 percent of Medicaid recipients age 12 to 64 have a diagnosed substance use disorder, and treatment is key to addressing overdoses, deaths and other health or social complications, KFF reported. So could tackling substance use disorders in turn reduce costs for the Medicaid program? Here's what experts told Newsweek. Photo-illustration by Newsweek/Getty/Canva Why Are Medicaid Costs Higher for Those With Substance Use Disorders? The reason Medicaid enrollees with substance use disorders have higher health costs is because they often also have additional health complications, Dr. Joshua Lynch, professor of emergency and addiction medicine at the University at Buffalo Jacobs School of Medicine and Biomedical Sciences, New York, told Newsweek. This could be physical health conditions, such as hypertension, high cholesterol and diabetes, or mental health disorders, "which can lead to more complex health care needs," he added. Those with substance use disorders also may "experience more fragmented care and more challenging access to high quality, lower cost care and preventative services," Lynch said. They may also struggle to work, or stay in work, and this may "contribute to increased reliance on higher-cost healthcare services," he added. Many Americans with substance use disorders also go undiagnosed, Brendan Saloner, professor of health policy and management at the John Hopkins Bloomberg School of Public Health, Maryland, told Newsweek. He added that those with substance addiction can have a lot of problems, such as the risk of overdose, or contracting blood-borne diseases like HIV or hepatitis C, as well as other issues, so "it's much better to get people into care proactively then to wait for their problems to become a crisis." The higher costs for those with substance use disorders, therefore, could "reflect the devastating physical consequences of substance use itself," Heidi Allen, professor of social work at the Columbia University School of Social Work, New York, told Newsweek, pointing to overdoses, increased vulnerability for chronic illness and exposure to infectious diseases. It's also not just about health complications, John Kelly, professor of psychiatry at Harvard Medical School and director of the Recovery Research Institute at Massachusetts General Hospital, told Newsweek. "The nature of these disorders means also that, on average, in the Medicaid population, individuals suffering from substance use disorder tend to have more social instability in terms of secure housing, employment, and criminal justice complications. These all contribute to increased costs," he said. Could Tackling Substance Use Disorders Reduce Medicaid Costs? While tackling substance use disorders may not slash Medicaid costs in the short term, as it would require investment in prevention and treatment, it could have positive economic impacts in the long run. "Prioritizing substance use treatment for enrollees might not reduce Medicaid costs in the short term, since we would expect more Medicaid enrollees to engage with treatment, which itself costs money," Allen said. However, she added that "it could certainly improve the health of enrollees, which might result in Medicaid savings down the road." If patients also have access to high-quality treatment and are able to manage their condition, "they have a lower reliance on high-cost health care such as emergency visits and inpatient hospitalizations," Lynch said. He added that other comorbidities also become more manageable, while housing stability and employment turn more achievable. "All of these will lead to a decrease in overall Medicaid spending," he said. Kelly also said he thought that tackling substance use disorders could reduce costs for Medicaid, adding that "focus on earlier intervention, and better implementation of care coordination will result in reduced use of more expensive acute medical care services, as well as prevention of the contraction of more chronic disease such as alcohol-associated liver diseases, HIV and hepatitis infections." "I am very confident that it would help to prevent some long-term costs to the program and would have a huge impact on other non-health needs like employment and reduced incarceration," Saloner said. But he added that whether it fully pays for itself, or saves money, is a more difficult question to answer. "We have some older studies showing that substance use care can offset lots of costs to society, but purely from the perspective of the Medicaid budget it's hard to say. The quality of life gains make it very cost-effective, whether or not it's cost saving," he said. Carrie Fry, professor in the department of health policy at Vanderbilt University School of Medicine, Tennessee, told Newsweek: "Research shows that addressing substance use disorder with effective, evidence-based treatments reduces Medicaid costs." In order to cut Medicaid costs, Fry said, making it easier for people with substance use disorders "to start and remain on effective treatment" would be an important step in the process. "For opioid use disorder, this means expanding availability of medications for opioid use disorder including methadone, buprenorphine, and naltrexone," she said. She added that only about half of Medicaid enrollees with an opioid use disorder receive evidence-based treatment in a given year. "So, treatment is an important first step to addressing the burden of substance use disorders in Medicaid and can reduce or prevent additional downstream costs," Fry said. She added that reducing the prevalence of substance use disorder via prevention will "require a more comprehensive approach to addressing broader social conditions that lead to increased risk of developing a substance use disorder."
Newsweek
a day ago
- Newsweek
FBI Working With India to Disrupt Chinese Fentanyl Network—Kash Patel
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Federal Bureau of Investigation (FBI) Director Kash Patel told podcaster Joe Rogan during a Friday episode that the agency is working with the Indian government to dismantle global fentanyl networks, which he said originate in China. Newsweek has reached out to the FBI's press office, the Indian Government's Ministry of External Affairs, and the Chinese Embassy in Washington for comment via email on Saturday. Why It Matters President Donald Trump has made combating the opioid crisis, particularly the influx of illicitfentanyl, a central focus of his administration's policies. Earlier this year, to address the sources of fentanyl trafficking, Trump imposed tariffs on imports from China, Mexico, and Canada. There are some legitimate medical uses for fentanyl. The opioid crisis has far-reaching impacts across the country. In 2024, the United States witnessed a significant decrease in opioid-related overdose deaths, dropping from 110,037 in 2023 to 80,391 in 2024, according to data from the U.S. Centers for Disease Control and Prevention (CDC). Rogan, host of The Joe Rogan Experience podcast, is one of the most-listened-to media figures, drawing an audience of roughly 11 million listeners. What To Know Patel told Rogan that when he joined the bureau, he launched a "massive enterprise" to target companies in China that manufacture "fentanyl precursors." He said that while China may not produce the drug in its final form, it supplies the key ingredients used to make fentanyl, calling the country the "root of the problem." The U.S.-China Economic and Security Review Commission, which provides recommendations to Congress, stated in an August 2021 finding that "China remains the primary country of origin for illicit fentanyl and fentanyl-related substances trafficked into the United States." Patel said during the interview with Rogan that the country has been shipping the precursors "to places like India—and I'm also doing operations in India—and they're having the Mexican cartels now make this fentanyl down in Mexico." In March, the Chinese government published a white paper laying out its purported efforts to crack down on fentanyl trade and hit back at U.S. criticism as Washington imposed tariffs over the issue. "I literally just got off the phone with the Indian government, I said: 'I need your help. This stuff's coming into your country and then they're moving it from your country because India's not consuming fentanyl...I need you and your help,'" the FBI director told Rogan. He explained the FBI is "working with the heads of their [the Indian] government, law enforcement authorities to say, 'We're going to find these companies that buy it and we're going to shut them down. We're going to sanction them; we're going to arrest them where we can. We're going to indict them in America if we can. We're going to indict them in India if we can.'" He reiterated that "this is a global problem." Patel said the Chinese Communist Party (CCP) isn't partaking in the trade for profitability reasons, but rather, "in my opinion, the CCP have used it as a directed approach because we are their their long-term game is how do I, in my opinion, kneecap the United States of America, our largest adversary?" suggesting that the drug allows them to "take out generations of young men and women." Tensions between Washington and Beijing have been high over a slew of issues, including tariff policies and national security issues. In May, federal authorities arrested 16 individuals and seized over 400 kilograms of the drug in the largest fentanyl bust in Drug Enforcement Administration (DEA) history. FBI Director Kash Patel is seen in Washington on May 8. FBI Director Kash Patel is seen in Washington on May 8. AP Photo/Jose Luis Magana What People Are Saying U.S. Treasury Secretary Scott Bessent told CNBC in mid-May: "I have a personal stake in this. There are two very close friends [who] lost children to this terrible scourge. Hundreds of thousands of Americans die every year. And I think that we saw here in Geneva the Chinese are now serious about assisting the U.S. in stopping the flow of precursor drugs." A spokesperson for the Chinese foreign ministry said in March: "Facts speak louder than words. The U.S. is spreading all kinds of false information on the fentanyl issue, smearing and scapegoating China, and hiking tariffs on Chinese imports over fentanyl." President Donald Trump wrote in an April 24 Truth Social post: "...By the way, Fentanyl continues to pour into our Country from China, through Mexico and Canada, killing hundreds of thousands of our people, and it better stop, NOW!" What Happens Next? It is unclear what the partnership looks like, but according to Patel it is ongoing.
